S'abonner

Timing of birth and adverse pregnancy outcomes in cases of prenatally diagnosed vasa previa: a systematic review and meta-analysis - 20/07/22

Doi : 10.1016/j.ajog.2022.03.006 
Samantha J. Mitchell a, , Georgia Ngo a, Kimberly A. Maurel, RN, MSN, CNS b, Junichi Hasegawa, MD, PhD c, Tatsuya Arakaki, MD, PhD d, Yaakov Melcer, MD e, f, Ron Maymon, MD e, f, Françoise Vendittelli, MD, PhD g, Alireza A. Shamshirsaz, MD h, Hadi Erfani, MD, MPH h, Scott A. Shainker, DO i, Antonio F. Saad, MD j, Marjorie C. Treadwell, MD k, Ashley S. Roman, MD, MPH l, Joanne L. Stone, MD m, Daniel L. Rolnik, MD, PhD n
a Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia 
b Clinical Services Division, The Mednax Center for Research, Education, Quality and Safety, Sunrise, FL 
c Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan 
d Department of Obstetrics and Gynecology, Showa University School of Medicine, Shinagawa-Ku, Tokyo, Japan 
e Department of Obstetrics and Gynecology, Shamir Medical Center (formerly Assaf Harofeh Medical Center), Be’er Ya’akov, Israel 
f Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 
g Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, Institut Pascal, F-63000 Clermont-Ferrand, France 
h Division of Fetal Therapy and Surgery, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX 
i Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 
j Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 
k University of Michigan Health, Ann Arbor, MI 
l Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, NYU Langone Health, New York, NY 
m Icahn School of Medicine at Mount Sinai, New York, NY 
n Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia 

Corresponding author: Samantha J. Mitchell.

Abstract

Objective

The ideal time for birth in pregnancies diagnosed with vasa previa remains unclear. We conducted a systematic review aiming to identify the gestational age at delivery that best balances the risks for prematurity with that of pregnancy prolongation in cases with prenatally diagnosed vasa previa.

Data Sources

Ovid MEDLINE, PubMed, CINAHL, Embase, Scopus, and Web of Science were searched from inception to January 2022.

Study Eligibility Criteria

The intervention analyzed was delivery at various gestational ages in pregnancies prenatally diagnosed with vasa previa. Cohort studies, case series, and case reports were included in the qualitative synthesis. When summary figures could not be obtained directly from the studies for the quantitative synthesis, authors were contacted and asked to provide a breakdown of perinatal outcomes by gestational age at birth.

Methods

Study appraisal was completed using the National Institutes of Health quality assessment tool for the respective study types. Statistical analysis was performed using a random-effects meta-analysis of proportions.

Results

The search identified 3435 studies of which 1264 were duplicates. After screening 2171 titles and abstracts, 140 studies proceeded to the full-text screen. A total of 37 studies were included for analysis, 14 of which were included in a quantitative synthesis. Among 490 neonates, there were 2 perinatal deaths (0.4%), both of which were neonatal deaths before 32 weeks’ gestation. In general, the rate of neonatal complications decreased steadily from <32 weeks’ gestation (4.6% rate of perinatal death, 91.2% respiratory distress, 11.4% 5-minute Apgar score <7, 23.3% neonatal blood transfusion, 100% neonatal intensive care unit admission, and 100% low birthweight) to 36 weeks’ gestation (0% perinatal death, 5.3% respiratory distress, 0% 5-minute Apgar score <7, 2.9% neonatal blood transfusion, 29.2% neonatal intensive care unit admission, and 30.9% low birthweight). Complications then increased slightly at 37 weeks’ gestation before decreasing again at 38 weeks’ gestation.

Conclusion

Prolonging pregnancies until 36 weeks’ gestation seems to be safe and beneficial in otherwise uncomplicated pregnancies with antenatally diagnosed vasa previa.

Le texte complet de cet article est disponible en PDF.

Key words : blood transfusion, cesarean, fetal hemorrhage, neonatal outcomes, perinatal death, prematurity, stillbirth, vasa previa


Plan


 Ms Samantha J. Mitchell and Ms Georgia Ngo are co-first authors.
 The authors report no conflict of interest.
 This study received no financial support.
 This study was registered with the International Prospective Register of Systematic Reviews under identifier CRD42020186416 and was registered on May 7, 2020.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 227 - N° 2

P. 173 - août 2022 Retour au numéro
Article précédent Article précédent
  • Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: a systematic review and network meta-analysis
  • Ha T. Nguyen, Montarat Thavorncharoensap, Toi L. Phung, Thunyarat Anothaisintawee, Usa Chaikledkaew, Abhasnee Sobhonslidsuk, Pattarawalai Talungchit, Nathorn Chaiyakunapruk, John Attia, Gareth J. McKay, Ammarin Thakkinstian
| Article suivant Article suivant
  • The incidence of wound complications following primary repair of obstetric anal sphincter injury: a systematic review and meta-analysis
  • Nicola Adanna Okeahialam, Ka Woon Wong, Ranee Thakar, Abdul H. Sultan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.